CompanyAPVONasdaqSeattle, WA

Aptevo Therapeutics

Aptevo Therapeutics develops multispecific immunotherapies for cancer using its ADAPTIR and ADAPTIR-FLEX platform technologies.

SEC EDGAR ClinicalTrials.gov aptevotherapeutics.com

8-KSep 24Latest SEC filing, period to Sep 24

Sep 3Latest story

September 2026

Aptevo files prospectus for resale of over 6.4 million warrant shares

Sep 3FinancingAptevo Therapeutics

August 2026

Aptevo Therapeutics discloses $3.47 million private placement, registers warrant shares for resale

Aug 26FinancingAptevo Therapeutics

Aptevo reports frontline AML data for mipletamig, targets Phase 2 talks in early 2027

Aug 14Quarterly updateAptevo Therapeutics

Aptevo closes $4.5 million warrant inducement and PIPE financing

Aug 13PartnershipAptevo Therapeutics

June 2026

Aptevo gets $1.5 million grant to advance solid tumor immunotherapy APVO451

Jun 30PartnershipAptevo Therapeutics